Companies › Lakewood-Amedex
1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nu-3 Topical antimicrobial gel | – | Phase 2 | Diabetic Foot Ulcers (DFUs) | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07565506 | Nu-3 | Phase 2 | Diabetic Foot Ulcers (DFUs) | Infectious disease | Jan 2027 |
Cash and short-term investments of $5m on 2026-06-30; operating cash outflow about $5m a year; runway about 11 months at that burn, to Jun 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
60 Degrees Pharmaceuticals Traws Pharma Acurx Pharmaceuticals Amplexd Therapeutics Sano Chemicals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.